In addition, we did not suggest that umbilical cord tissue would act as a reservoir for cotinine when we discussed the physicochemistry of cotinine and the makeup of the umbilical tissue. The pharmacokinetic flow of cotinine with respect to mom's blood, placenta, umbilical tissue and fetal blood is not fully elucidated. Hence, cotinine, having a longer half-life than nicotine, is still detectable in the tissue and may be indicative of smoke exposure, but not quantitative for amounts of exposure. Cord serum can be used to quantitate the amount of exposure, and when available may be superior. There are times, however, when cord serum is not available, as it was not collected. Our method provides a means to assess tobacco exposure in those cases when the placenta and cord are available but not the serum. We read with great interest the recent paper by Isemann et al.
1
In this retrospective review of 128 neonates the severity of neonatal abstinence syndrome (NAS) was mitigated by reducing maternal methadone dose during pregnancy and encouraging breastfeeding. We fully support these conclusions but believe there to be some shortcomings in the study including failure to document the incidence of NAS in the population studied. We caution against using length of stay as a proxy for NAS severity; these infants typically have complex social backgrounds and often require prolonged hospital stays simply to facilitate discharge planning.
Isemann et al. 1 note that optimal management of NAS has been confounded by inconsistencies in the literature; it is unfortunate that they did not consider our review 2 of 444 mother-infant pairs (by far the largest cohort studied to date), which provides a great deal of clarity. All our mothers were prescribed substitute methadone (median dose 50 mg per day, range 5-150 mg), and at least 80% used additional illicit drugs. 45.5% of infants received pharmacological treatment for NAS. The odds ratio of requiring treatment for NAS was independently related to prescribed maternal methadone dose (rather than associated polydrug misuse) and was halved by breastfeeding.
The main procedural difference between our practice and that in Cincinnati is the use of oral morphine rather than methadone as first-line pharmacotherapy for NAS. We both administer medication every 4 h (despite the considerably longer half-life of methadone) and we both use phenobarbital as a second-line agent with potential for use at home. In our unit, NAS per se is not necessarily an indication for admission to the Neonatal Unit, and infants may receive pharmacological treatment while remaining with their mothers in the postnatal ward.
The authors and their extended clinical team are to be commended on achieving such a high rate of breast milk feeding (60.8%). Although we question the accuracy of reviewing 'nursing flow sheets y to determine the proportion of total intake that was comprised of MBM (maternal breast milk)' unless infants received measured volumes of expressed breast milk rather than suckling, the observed association between maternal breast milk feedings and shorter duration of neonatal methadone treatment complements our own observations and supports encouragement of breastfeeding in this population. Contrary to Isemann et al.,
1 we did not observe any cases of rebound withdrawal symptoms amongst the 51 infants in our group who were still breastfeeding at discharge, but we agree wholeheartedly that further studies in this area are warranted. We described almost three times as many preterm infants (90 versus 36) and observed no association between preterm birth and the development of NAS.
To conclude, we are delighted that Isemann's findings are generally consistent with our own and we are optimistic that the growing evidence base will put to rest (finally) the debate over conflicting results of older, smaller studies of NAS. Obstetric and Neonatal teams now have sound data from both sides of the Atlantic to inform guideline development, thus improving and standardising clinical care provided to a vulnerable group of infants.
C Dryden 1 and H Mactier
We applaud Dryden and Mactier for their extensive analysis of maternal factors in opiate-addicted women which place their infants at risk for severe neonatal abstinence syndrome (NAS) requiring pharmacologic treatment. The intent of our study was to assess factors associated with response to a specified pharmacotherapy protocol for NAS. Determining the incidence of NAS at our institution was outside of the scope of our study. It is reassuring that where our works overlapped, we came to similar conclusions. We were remiss in not citing their work and appreciate the opportunity to clarify some of our methodology and results. The differences between the standards of care of infants with NAS at our institution and those of Dryden and Mactier may help to explain some of the questions and concerns expressed in their Letter to the Editor. At our hospital, mothers are often discharged after 48 h of vaginal delivery or after 72 h following delivery by cesarean section. In contrast, Dryden and Mactier reported that mothers are able to room-in with their infants for up to 10 days. (This ability to treat the infant in the presence of the mother, maintaining the physical maternal-infant bonding, is highly desirable and these services are commendable.)
After a mother is discharged from our hospital, she is highly encouraged to provide expressed human milk to the hospital for subsequent bottle feedings for her infant in her absence. However, logistical problems such as transportation, care of older children and the demands of her own medical care encumber these mothers and serve as impediments to visiting. Most of the feedings of infants being treated for NAS at our institution, therefore, is either expressed mother's milk or formula. The calculation of the proportion of human milk intake was derived from the exact volume of expressed mother's milk fed to the infants, and could easily be abstracted from the flowsheet. In the uncommon event that a mother visited her infant and elected to feed directly at the breast, the determination of proportion of total intake comprising of maternal breast milk was a ratio of the number of breast feedings plus subsequent expressed-bottle feedings, divided by the total number of feedings for the day. The identification of rebound withdrawal symptoms, which occurred in infants from our study whose human milk intake was abruptly weaned, may have been obfuscated in the study by Dryden and Mactier due to the lower incidence of breast feeding at the time of discharge. They did report three infants who were started on phenobarbital therapy after being discharged home, but it is unclear whether these infants were on mother's milk at the time of discharge. We agree that further work is needed to identify infants at risk for rebound NAS.
We understand the caution by Dryden and Mactier regarding the use of length-of-stay as a proxy for NAS severity, particularly when pre-term infants are included in the sample set. However, at our institution, discharge planning begins at the time of admission. The goal is to have the social aspects of disposition completed by the time the infant's clinical problems are resolved. It is unusual that questions pertaining to disposition would extend an infant's hospitalization by more than a day. Therefore, we feel confident that the length-of-stay predictably coincides with days of pharmacotherapy at our institution, and this was the rationale for its use as a reflection of the severity of NAS. Our data confirm this as the length-of-stay in term infants (mean 17.3 days) roughly equates to the duration of methadone therapy (mean 12.4 days), plus the age at initiation (mean 1.8 days), plus the protocolmandated 2-day observation after cessation of methadone pharmacotherapy. Incidentally, the mean duration of methadone therapy in term infants in our study is only 1 day longer than was reported by Dryden and Mactier in their experience with morphine, which they rightly point out, is a shorter acting agent, and infant's response to tapering of the dose would be expected to occur more readily. However, with most of our NAS population receiving methadone through mother's milk, our preference is to maintain methadone as first-line monotherapy in treating infants with NAS.
